1620172-81-7

Basic information

• Product Name: 5-(2-chloro-phenyl)-3-phenyl-4,5-dihydro-pyrazole-1-carbothioic acid [4,6-bis-(4-fluorophenylamino)-[1,3,5]triazin-2-yl]-amide
• Synonyms: 5-(2-chloro-phenyl)-3-phenyl-4,5-dihydro-pyrazole-1-carbothioic acid [4,6-bis-(4-fluorophenylamino)-[1,3,5]triazin-2-yl]-amide
• CAS NO: 1620172-81-7
• Molecular Weight: 613.093
• Mol File: 1620172-81-7.mol

Chemical Properties

• CAS DataBase Reference: 5-(2-chloro-phenyl)-3-phenyl-4,5-dihydro-pyrazole-1-carbothioic acid [4,6-bis-(4-fluorophenylamino)-[1,3,5]triazin-2-yl]-amide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-chloro-phenyl)-3-phenyl-4,5-dihydro-pyrazole-1-carbothioic acid [4,6-bis-(4-fluorophenylamino)-[1,3,5]triazin-2-yl]-amide(1620172-81-7)
• EPA Substance Registry System: 5-(2-chloro-phenyl)-3-phenyl-4,5-dihydro-pyrazole-1-carbothioic acid [4,6-bis-(4-fluorophenylamino)-[1,3,5]triazin-2-yl]-amide(1620172-81-7)

Safety Data

• Hazardous Substances Data: 1620172-81-7(Hazardous Substances Data)

Upstream product

• 371-40-4 4-fluoroaniline 
• 1146963-14-5 amino[5-(2-chlorophenyl)-3-phenyl-2-pyrazolin-1-yl]methane-1-thione 
• 131468-32-1 6-chloro-N²,N⁴-bis(4-fluorophenyl)-1,3,5-triazine-2,4-diamine 
• 98-86-2 acetophenone 
• 89-98-5 2-chloro-benzaldehyde 
• 3300-67-2 3-(2-chlorophenyl)-1-phenylpropenone 

Relevant articles and documents

Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate

Impressed by the exceptional antibacterial activity exhibited by our earlier designed molecules originating from 1,3,5-triazine, the present study was undertaken to synthesize a novel series of 1,3,5-triazine-pyrazole conjugates to bring diversity around the core skeleton. The target analogues showed potent antibacterial activity against tested Gram-positive and Gram-negative microorganisms. The toxicity and metabolic site prediction studies were also held out to set an effective lead candidate for the future antibacterial drug discovery initiatives.